Continuing Education Information
Joint Accreditation Statement
The Postgraduate Institute for Medicine designates this live activity for a maximum of 5.0 AMA PRA Category 1 Credits™.
Continuing Pharmacy Education
Postgraduate Institute of Medicine designates this continuing education activity for 5.0 contact hours (0.5 CEUs) of the Accreditation Council for Pharmacy Education.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 5.0 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses to be determined.
American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Learning Objectives
Upon completion of this activity, participants should be able to:
-
Describe the rationale for common approaches to cancer immunotherapy.
-
Identify the appropriate clinical management of immune-related adverse events of immunotherapy agents.
-
Implement cancer immunotherapy treatments for melanoma, lung, genitourinary, head and neck, breast and gynecologic, gastrointestinal, microsatellite instability high and/or hematologic cancers into clinical practice appropriately.
Technology Requirements
For optimal completion of this program, the attendee will need a computer/laptop with a strong WiFi connection and the ability to stream video.
Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.
View the SITC Meeting Code of Conduct.
Avoid Fraudulent ACI Registration Websites
Recently, the SITC office received communication about a fraudulent registration website for one of our ACI programs. To help ensure others don’t mistakenly register on an unauthorized, third-party website, we're proactively informing you to ensure you’re able to safely register for the event through the official SITC website, and so that you can confirm the communication you receive is truly from SITC.
The single, official registration webpage for this ACI program is available here: https://sitc.execinc.com/edibo/ACI20-21TX. All official forthcoming ACI registration information will come from an email address ending in @sitcancer.org.
If you have any questions, please contact the SITC office at events@sitcancer.org or 414-271-2456.
Americans with Disabilities Act
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact SITC Staff prior to the live event at (414) 271-2456 or via email education@sitcancer.org.
The 2020-2021 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
The 2020-2021 Advances in Cancer Immunotherapy™ series is brought to you in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.
The 2020–2021 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc. and Merck & Co., Inc.